Market Overview - The RNA therapy market is projected to grow from USD 18.77 billion in 2025 to USD 19.70 billion in 2026, with a compound annual growth rate (CAGR) of 6.40%, reaching USD 28.99 billion by 2032, driven by clinical proof, supply chain improvements, and regional investments [1][6]. Therapeutic Applications - RNA-based therapeutics are applicable in various therapeutic areas, including cardiovascular diseases, genetic disorders, infectious diseases, metabolic and neurological diseases, oncology (hematological cancers and solid tumors), and rare conditions like Gaucher disease and sickle cell disease, broadening the market scope [4]. Delivery Platforms - Delivery platforms for RNA therapies include exosomes, lipid nanoparticles, polymer carriers, and viral vectors, which influence targeting ability, immune response, production scale, and clinical trial timelines, allowing developers to customize delivery methods [4]. End-User Groups - The end-user groups for RNA therapies consist of biotechnology companies, pharmaceutical manufacturers, hospitals, clinics, and research institutes, shaping commercialization strategies and market entry timings [4]. Geographic Regions - The RNA therapy market spans the Americas, Europe, the Middle East & Africa, and Asia-Pacific, each presenting unique regulatory challenges, adoption rates, and infrastructure capabilities, necessitating navigation of regional nuances [4]. Strategic Considerations - Successful RNA therapy development relies on scientific innovation, delivery platform selection, supply chain resilience, and partnerships with healthcare institutions, with strategic distinction depending on aligning delivery technologies with pipeline priorities [4][9]. Industry Collaboration - Collaborative efforts between biotech firms and established pharmaceutical companies are accelerating clinical adoption and easing operational and regulatory integration, responding to heightened end-user demands for rapid production cycles and targeted therapies [9]. Market Insights - The report provides prioritized insights on RNA therapy pipelines and delivery technologies, aiding in adapting regulatory and supply chain strategies to shifting policies and supporting global operational flexibility [9].

Core Insights - The report provides a comprehensive analysis of global biologics sales, including various categories such as cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, and RNA-based drugs [1][3][5] - It highlights sales data, growth trends, and rankings of top biologics, making it essential for biopharma professionals, investors, and market analysts [1][2] Sales Data Overview - The report compiles and analyzes sales data for originator recombinant therapeutic proteins and antibodies for the year 2024, including publicly available data for biosimilars and new biologic modalities [3][5] - Sales data from 2012 to 2024 are summarized, showing growth rates and the percentage of antibody sales relative to total biologics sales [5] Product Categories - Individual product sales data are categorized into groups such as cancer antibodies, non-TNF anti-inflammatory mAbs, cardiometabolic antibodies, and more [9][10] - Target-specific sales data for cancer antibodies and non-TNF anti-inflammatory antibodies are calculated for 2024, covering various therapeutic areas [7][12] Market Trends - The report emphasizes the commercial success of novel antibody drug modalities, including antibody-drug conjugates and bispecific antibodies, with sales and growth rates presented from 2012 to 2024 [16] - A total of 75 innovator therapeutic antibodies and proteins achieved blockbuster status in 2024, each exceeding sales of US$ 1 billion [16] Company Rankings - A ranking list of the top 30 companies regarding biologics sales in 2024 is provided, along with company-specific sales data for biosimilars from 2020 to 2023 [16] - The report includes detailed sales data for various biologic products, highlighting the competitive landscape within the industry [14][16]